APSR2026-685

Yes
Late-Breaking
Submitted
Oral Presentation
AO06-007
 
 
https://storage.unitedwebnetwork.com/files/1285/1221116-46903-APSR 685_439694.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Nur Puspita Sari Siregar * Faculty of Medicine Universitas Indonesia Department of Pulmonology and Respiratory Medicine Jakarta Indonesia
Andika Chandra Putra - Faculty of Medicine Universitas Indonesia Department of Pulmonology and Respiratory Medicine Jakarta Indonesia
Jamal Zaini - Faculty of Medicine Universitas Indonesia Department of Pulmonology and Respiratory Medicine Jakarta Indonesia
Lee Son Tran - Gene Solution Research and Development Ho Chi Minh Vietnam
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Nur Puspita Sari
Siregar
nurpuspitasari.siregar@gmail.com
+628561732256
31-40
Indonesia
Original Research
Plasma cell-free DNA methylation profiles and clinical correlates in Indonesian lung cancer patients
Maximum 25 words
Abstract Content
Aberrant DNA methylation is a key epigenetic hallmark of lung carcinogenesis and represents a promising non-invasive biomarker when detected in circulating cell-free DNA (cfDNA). This study aimed to identify differentially methylated regions (DMRs) in plasma cfDNA from lung cancer patients compared with benign controls and to evaluate their associations with histopathological subtype and clinical stage.
This cross-sectional analytic study included 26 patients with histologically confirmed lung cancer (NSCLC, n=21; SCLC, n=5) treated at RSUP Persahabatan. Plasma cfDNA underwent sodium bisulfite conversion followed by next-generation sequencing–based methylation analysis. Differential methylation was assessed using Benjamini–Hochberg false discovery rate (FDR) correction, with adjusted p<0.05 considered statistically significant. Global methylation levels were compared according to histopathological subtype and clinical stage using appropriate statistical methods.
Twenty-six FDR-adjusted DMRs were identified, comprising 20 hypermethylated and 6 hypomethylated regions in lung cancer compared with benign controls. The most strongly hypermethylated loci (adjusted p<0.01) involved HLX-AS1 and the protocadherin gamma cluster, including PCDHGA3, while the most strongly hypomethylated locus was CYP2W1. Cumulative cfDNA methylation index was significantly higher in SCLC rather than NSCLC (0.394±0.089 vs 0.255±0.115; p=0.019). Median methylation indexes increased with advancing clinical stage and advanced-stage disease (III–IV) demonstrated higher levels than early-stage disease (I–II), showing a borderline trend (p=0.077).
Plasma cfDNA methylation profiling reveals a predominant hypermethylation signature in lung cancer and demonstrates associations with histopathological subtype and clinical stage. Given the substantial and growing burden of lung cancer in the Asia-Pacific region, particularly in Southeast Asia, the identification of non-invasive epigenetic biomarkers such as cfDNA methylation signatures may contribute to improved risk stratification and disease characterization. These findings from a cohort at RSUP Persahabatan, Jakarta, underscore the importance of region-specific molecular profiling in addressing the heterogeneous epidemiology of lung cancer in the Asia-Pacific population. Larger studies are warranted to validate these results.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
circulating cell-free DNA, DNA methylation, lung cancer
maximum 3 keywords and no abbreviations, separated by commas
 
317